Yesterday, Oct. 21, 2015, 31 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $151.90 to $2,899,511.25.

Highlighted Stocks Traded by Insiders:

Ares Capital Corporation (ARCC) - FREE Research Report

Bartlett Steve, who is Director at Ares Capital Corporation, bought 100 shares at $15.22 on Oct. 21, 2015. Following this transaction, the Director owned 4,800 shares meaning that the stake was boosted by 2.13% with the 100-share transaction.

The shares most recently traded at $15.27, up $0.05, or 0.33% since the insider transaction. Historical insider transactions for Ares Capital Corporation go as follows:

  • 4-Week # shares bought: 100
  • 12-Week # shares bought: 85,681
  • 24-Week # shares bought: 85,981

The average volume for Ares Capital Corporation has been 1.8 million shares per day over the past 30 days. Ares Capital Corporation has a market cap of $4.8 billion and is part of the financial sector and financial services industry. Shares are down 3.59% year-to-date as of the close of trading on Wednesday.

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. The stock currently has a dividend yield of 10%. The company has a P/E ratio of 8.2. Currently, there are 10 analysts who rate Ares Capital Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCC - FREE

TheStreet Quant Ratings rates Ares Capital Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Ares Capital Corporation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

China Biologic Products (CBPO) - FREE Research Report

Gao David, who is Chief Executive Officer at China Biologic Products, sold 458 shares at $105.01 on Oct. 21, 2015. Following this transaction, the Chief Executive Officer owned 616,542 shares meaning that the stake was reduced by 0.07% with the 458-share transaction.

The shares most recently traded at $99.90, down $5.11, or 5.12% since the insider transaction. Historical insider transactions for China Biologic Products go as follows:

  • 4-Week # shares sold: 31,108
  • 12-Week # shares sold: 31,108
  • 24-Week # shares sold: 5.3 million

The average volume for China Biologic Products has been 220,400 shares per day over the past 30 days. China Biologic Products has a market cap of $2.6 billion and is part of the health care sector and drugs industry. Shares are up 52.52% year-to-date as of the close of trading on Wednesday.

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. The company has a P/E ratio of 33.1. Currently, there are 3 analysts who rate China Biologic Products a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CBPO - FREE

TheStreet Quant Ratings rates China Biologic Products as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full China Biologic Products Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RenaissanceRe Holdings (RNR) - FREE Research Report

Curtis Ross, who is SVP,Chief Underwriting Officer at RenaissanceRe Holdings, sold 5,000 shares at $110.00 on Oct. 21, 2015. Following this transaction, the SVP,Chief Underwriting Officer owned 89,892 shares meaning that the stake was reduced by 5.27% with the 5,000-share transaction.

The shares most recently traded at $110.71, up $0.71, or 0.64% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 8,500
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 19,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 37,293

The average volume for RenaissanceRe Holdings has been 333,900 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $5.1 billion and is part of the financial sector and insurance industry. Shares are up 13.06% year-to-date as of the close of trading on Wednesday.

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company operates in three segments: Catastrophe Reinsurance, Specialty Reinsurance, and Lloyd's. The stock currently has a dividend yield of 1.08%. The company has a P/E ratio of 9.5. Currently, there are 3 analysts who rate RenaissanceRe Holdings a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNR - FREE

TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.